Robert Davis, Merck CEO
November 1, 2021 07:07 AM EDT
Deals

Mer­ck de­lays $11.5B Ac­celeron buy­out to give an­titrust watch­dog 'ad­di­tion­al time for re­view'

Nicole DeFeudis

Editor

Mer­ck’s $11.5 bil­lion Ac­celeron Phar­ma buy­out may not hap­pen quite as soon as the Ke­nil­worth, NJ-based phar­ma com­pa­ny had hoped.

On Fri­day, Mer­ck

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Pfiz­er hires ex-FDA deputy Pa­trizia Cavaz­zoni as chief med­ical of­fi­cer

Pfiz­er wants in on Sum­mit’s goal to beat Keytru­da via ADC com­bos

Post-Hoc: Phar­ma CEOs' al­ter­na­tive re­al­i­ty with Trump

Sanofi, Te­va bol­ster case for IBD drug with Phase 2 da­ta, de­spite po­ten­tial com­pe­ti­tion

FDA lifts hold on En­trada's Duchenne drug af­ter two years

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times